The purpose of this study is to compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer.

This study is being done to see if losing weight may help prevent breast cancer from coming back (recurring).

This registry/tissue bank is focused on the collection of detailed information and biological samples on participants to help create a resource that will be helpful to researchers in future studies related to breast cancer.

The purpose of this study is find out what effects, both good and bad, an experimental drug called entinostat has on patients with breast cancer that is not able to be removed by surgery or has spread to another part of the body, when given together with the standard hormonal drug treatment, exemestane.

The purpose of this study is to compare getting more treatment with capecitabine (i.e. one of the usual approaches), to any good and bad effects of getting more treatment with a platinum-based chemotherapy (cisplatin or carboplatin), after surgery for patients with triple-negative breast cancer.

The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.

The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without cancer returning for patients with hormone responsive breast cancer that have had their cancer removed by surgery and have completed required chemotherapy or radiation.

The main purpose of this study is to compare any good and bad effects of using ABT-888 (Veliparib) (a “PARP” inhibitor) along with cisplatin to using cisplatin alone.

The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery.

The purpose of this study is to compare any good and bad effects patients with early stage non-small cell lung cancer that was surgically removed may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).